Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

49.84 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 49.84
Bid (Size) 50.72 (11)
Ask (Size) 51.87 (1)
Prev. Close 49.84
Today's Range 49.84 - 49.84
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest... 
Via Benzinga

Performance

YTD
+172.65%
+172.65%
1 Month
-4.19%
-4.19%
3 Month
-25.02%
-25.02%
6 Month
+132.68%
+132.68%
1 Year
+223.43%
+223.43%

More News

Read More
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Via Benzinga
Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
Via Benzinga
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data
Via Investor's Business Daily
Is Viking Therapeutics the Best Biotech Stock for You?
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
Via InvestorPlace
Is Viking Therapeutics Stock Running Out of Steam?
Via The Motley Fool
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Via The Motley Fool
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Via MarketBeat
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
Via The Motley Fool
3 Overlooked Giants-in-the-Making for Patient Investors
Via InvestorPlace
The 7 Best Under $10 Stocks to Buy in July 2024
Via InvestorPlace
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Via The Motley Fool
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
3 Biotech Moonshots With Imminent Catalyst Potential
Via InvestorPlace
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Via MarketBeat
Exposures Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Via MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Via MarketBeat
Exposures Product Safety
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
Via The Motley Fool
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Via The Motley Fool
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
Via InvestorPlace
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
Via InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.